

**21**  
Name of Journal: *World Journal of Hepatology*

Manuscript NO: 55384

Manuscript Type: MINIREVIEWS

**1**  
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update

Sofogianni A *et al.* NAFLD/GLP-1RAs

Areti Sofogianni, Athanasios Filippidis, Lampros Chrysavgis, Konstantinos Tziomalos, Evangelos Cholongitas

### Abstract

Non-alcoholic fatty liver disease (NAFLD) is the predominant cause of chronic liver disease worldwide. NAFLD progresses in some cases to non-alcoholic steatohepatitis (NASH), which is characterized, in addition to liver fat deposition, by hepatocyte ballooning, inflammation and liver fibrosis, and in some cases may lead to hepatocellular carcinoma. NAFLD prevalence increases along with the rising incidence of type 2 diabetes mellitus (T2DM). Currently, lifestyle interventions and weight loss are used as the major therapeutic strategy in the vast majority of patients with NAFLD. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used in the management of T2DM and do not

### Match Overview

1	Internet 69 words crawled on 28-Aug-2019 <a href="http://ikee.lib.auth.gr">ikee.lib.auth.gr</a>	1%
2	Internet 45 words crawled on 26-Sep-2019 <a href="http://link.springer.com">link.springer.com</a>	1%
3	Internet 43 words crawled on 06-Jul-2016 <a href="http://www.wjgnet.com">www.wjgnet.com</a>	1%
4	Internet 38 words crawled on 22-Jul-2019 <a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a>	1%
5	Internet 28 words crawled on 22-Feb-2020 <a href="http://www.mdpi.com">www.mdpi.com</a>	<1%
6	Internet 28 words crawled on 27-Aug-2019 <a href="http://journals.plos.org">journals.plos.org</a>	<1%
7	Internet 24 words crawled on 10-Feb-2020 <a href="http://onlinelibrary.wiley.com">onlinelibrary.wiley.com</a>	<1%
8	Crossref 17 words Philip Newsome, Sven Francque, Stephen Harrison, Vlad Ratzu et al. "Effect of semaglutide on liver enzymes and	<1%



ALL

IMAGES

VIDEOS

31,900 Results

Any time ▾

## [Effects of glucagon-like peptide-1 receptor agonists on ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209545>

Oct 28, 2014 · **Core tip:** The findings showed that glucagon-like peptide-1 receptor agonists (**GLP-1RAs**) may improve **liver function**, **fat content** and distribution, **lipid metabolism** and reduce the activity of **inflammatory cytokines** and their associated signal transduction pathways. Thus, we review here that **GLP-1RAs** are a potential method for pharmacologic treatment that can benefit patients with **non-alcoholic fatty liver disease** and **chronic inflammation**.

**Cited by:** 55**Author:** Xing-Chun Wang, Aaron M Gusdon, H...**Publish Year:** 2014

## [Glucagon like peptide-1 receptor agonists for the ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/28918389>

Due to their overall safety and efficacy, **glucagon-like peptide-1 receptor agonists (GLP-1 RAs)** are becoming one of the cornerstones for the management of both **obesity** and T2DM, and a novel alternative for the **treatment of NAFLD**. In this review, we will briefly summarize the status of **GLP-1RA** for the **treatment of obesity and NAFLD**.

**Cited by:** 19**Author:** Gauri Dhir, Kenneth Cusi**Publish Year:** 2018

## [Effects of glucagon-like peptide-1 receptor agonists on ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/25356042>

Oct 28, 2014 · Effects of **glucagon-like peptide-1 receptor agonists** on non-alcoholic **fatty liver disease** and inflammation. Wang XC(1), Gusdon AM(1), Liu H(1), Qu S(1). Author information: (1)Xing-Chun Wang, Shen Qu, Department of Endocrinology and Metabolism, Shanghai 10 People's Hospital, Tongji University, Shanghai 200072, China.

**Cited by:** 55**Author:** Xing-Chun Wang, Aaron M Gusdon, H...**Publish Year:** 2014





## Glucagon like peptide-1 receptor agonists for the ...

<https://www.ncbi.nlm.nih.gov/pubmed/28918389>

Due to their overall safety and efficacy, **glucagon-like peptide-1 receptor agonists (GLP-1 RAs)** are becoming one of the cornerstones for the management of both **obesity** and T2DM, and a novel alternative for the **treatment of NAFLD**. In this review, we will briefly summarize the status of **GLP-1RA** for the **treatment of obesity and NAFLD**.

Cited by: 19

Author: Gauri Dhir, Kenneth Cusi

Publish Year: 2018

## Effects of glucagon-like peptide-1 receptor agonists on ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209545>

Oct 28, 2014 · **Core tip:** The findings showed that glucagon-like peptide-1 receptor agonists (**GLP-1RAs**) may improve **liver function**, **fat content** and distribution, **lipid metabolism** and reduce the activity of **inflammatory cytokines** and their associated signal transduction pathways. Thus, we review here that **GLP-1RAs** are a potential method for pharmacologic treatment that can benefit patients with **non-alcoholic fatty liver disease** and **chronic inflammation**.

Cited by: 55

Author: Xing-Chun Wang, Aaron M Gusdon, Hua...

Publish Year: 2014

## GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428412>

Aug 20, 2012 · Non-alcoholic **fatty liver disease (NAFLD)**, one of the most common **liver** diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. **Glucagon-like peptide-1 (GLP-1)** is an incretin that increases insulin sensitivity and aids glucose metabolism.

Cited by: 59

Author: Jinmi Lee, Seok Woo Hong, Eun Jung Rh...


Publish Year: 2012

## Effects of glucagon-like peptide-1 receptor agonists on ...

<https://www.ncbi.nlm.nih.gov/pubmed/25356042>


## Non-Alcoholic Fatty Liver Disease

Medical Condition



A condition in which fat accumulates in the liver in people who drink little or no alcohol.

 Very common (More than 3 million cases per year in US)

 Requires lab test or imaging

 Treatments can help manage condition, no known cure

 Can last several years or be lifelong

The cause of non-alcoholic fatty liver disease is not clearly understood. It is associated with obesity, insulin resistance, hyperglycemia, and high levels of fat in blood. The condition does not usually cause symptoms. In some cases, fatigue, enlarged liver, and pain in the upper right abdomen is seen. Non-alcoholic fatty liver disease has no specific treatment. It involves treating underlying conditions such as obesity.